(National Institutes of Health)
Evotec AG, a biotechnology company in Hamburg, Germany announced today a research collaboration with Harvard University in Cambridge, Massachusetts and Howard Hughes Medical Institute (HHMI), in Chevy Chase, Maryland to discover and develop new diabetes treatments. The partnership aims to identify and develop physiological mechanisms and targets that regulate beta cell replication.
Beta cells are the predominant type of cell in the region of the pancreas that produces insulin. Therapies that trigger or support beta cell replication are expected to enhance or even restore the body’s ability to produce enough insulin to maintain optimal glycemic control and thus reduce diabetic complications.
Molecular biologist Douglas Melton at Harvard University, and an investigator at the Howard Hughes Medical Institute, will be the principal investigator. His laboratory focuses on the development of the pancreas and the use of stem cells to find new treatments for diabetes.
Evotec discovers and develops small molecule drugs with a platform and experience in the treatment of diseases related to neuroscience, pain, oncology, inflammation, and metabolic diseases.
Read more: Eli Lilly, Diabetes Foundation to Fund Insulin Cell Research
* * *
RSS - Posts
You must be logged in to post a comment.